Danaher sells the tools, chemicals, and instruments that scientists and doctors use every single day. Its three segments, Biotechnology, Life Sciences, and Diagnostics, cover everything from the filters used to make a cancer drug, to the test cartridges that tell a doctor whether a patient has tuberculosis, to the microscopes that let researchers see individual cells. The real engine is not the big machines. It is the consumables: the reagents, filters, antibodies, and assay kits that customers have to keep buying over and over again to keep their labs and hospitals running. That recurring-purchase model is what makes the revenue relatively predictable. The diagram below traces where the money goes.
How Danaher Makes Money
flowchart TD
A["Customers in 3 Markets"] --> B["Biotechnology Segment
$B revenue"]
A --> C["Life Sciences Segment
$L revenue"]
A --> D["Diagnostics Segment
$D revenue"]
B --> E["Recurring Products
80% of revenue"]
C --> E
D --> E
B --> F["Nonrecurring Products
20% of revenue"]
C --> F
D --> F
E --> G["Operating Margin
19.1%"]
F --> G
G --> H["Cash Flow
$5.3B free cash"]
H --> I["Strategic M&A
and R&D"]
I --> B
I --> C
I --> D
H --> J["DBS Culture
Continuous Improvement"]
J --> K["Innovation
and Efficiency"]
K --> E
K --> G
Five years of data tell a story of a company that grew fast during the pandemic era and has since been working through a hangover. Revenue peaked at $26.6 billion in 2022, then dropped as pandemic-related demand faded and customers in the biotechnology world worked through excess inventory they had stockpiled. By 2023 and 2024, revenue had settled back to $23.9 billion both years. In 2025 it edged up to $24.6 billion, with core sales growth of 2.0% once currency effects are stripped out.
Danaher Annual Revenue (2021 to 2025)
Revenue in billions of dollars. The 2022 peak reflected pandemic-era demand; the dip in 2023 to 2024 reflected customers drawing down inventory rather than placing new orders.
The cash picture tells a similar story. Operating cash flow was $8.4 billion in 2021 and $8.5 billion in 2022. By 2025 it had fallen to $6.4 billion. Free cash flow followed the same path, dropping from $7.1 billion in 2021 to $5.3 billion in 2025. The business still generates substantial cash. But the trajectory over five years is down, not up.
$7.4B
Free Cash Flow 2022
$5.3B
Free Cash Flow 2025
Free cash flow has fallen by roughly $2.1 billion over three years as pandemic-era tailwinds reversed.
Gross margins have held in a narrow band, between 58.7% and 61.4% over the five years. That consistency reflects the consumables model: when a lab is running, it needs Cytiva filters or Cepheid test cartridges regardless of what the broader economy is doing. The three segments perform very differently, though. Diagnostics, led by Beckman Coulter, Cepheid, and Radiometer, is the largest and most stable, generating $9.9 billion in sales in 2025 at a 26.7% operating margin. Biotechnology bounced back strongly in 2025, with sales up 8.0% year over year to $7.3 billion and an operating margin of 25.6%, driven by renewed consumables demand from large pharmaceutical companies. Life Sciences is the problem child right now: flat sales of $7.3 billion in 2025 and an operating margin that collapsed from 16.9% in 2023 to just 7.1% in 2025, weighed down by impairment charges and weak demand from academic and government research customers.
What is a consumables model?
Some companies sell a machine once and that is the end of the sale. A consumables model is different. The company sells the machine, and then the customer has to keep buying supplies to use it, like ink cartridges for a printer. For Danaher, the 'ink cartridges' are things like Cepheid test kits, Cytiva cell culture media, and Abcam antibodies. Customers are locked in by habit, training, and regulatory approval, so they rarely switch brands.
Net debt has moved in an encouraging direction over the period, falling from $19.6 billion in 2021 to $12.5 billion in 2023 after Danaher separated its Environmental and Applied Solutions division into a new independent company called Veralto in September 2023. Since then, net debt has nudged back up slightly to $13.8 billion in 2025, partly reflecting share repurchases.
2023
milestone
Veralto Separation Sharpens the Focus
In September 2023, Danaher spun off its Environmental and Applied Solutions businesses into a separate public company called Veralto. This left Danaher with only its Biotechnology, Life Sciences, and Diagnostics segments. The move simplified the business and reduced net debt, but it also removed a source of diversification. Danaher is now a purer bet on healthcare and life sciences demand.
The risks Danaher faces are specific and documented. Governments and insurers worldwide are cutting what they pay for medical products and services. China's volume-based procurement program forced Danaher to lower prices on its Diagnostics products in that market in 2025, and price decreases in the Diagnostics segment of 1.0% during 2025 were primarily attributed to that program. China represents approximately 11% of total sales, and a mid-single digit core sales decline in China in 2025 was only partially offset by growth elsewhere.
59%
Share of 2025 sales from outside the United States, creating broad exposure to currency swings, trade policy changes, and country-specific pricing rules.
Trade policy is an active headache, not a theoretical one. In 2025, new US tariffs added incremental costs of less than $300 million. Danaher largely offset those costs through supply chain changes, surcharges, and productivity actions. But the company's own filing warns that if it cannot continue to offset tariff costs, or if additional tariffs are imposed, revenue and profitability would be hurt. The US Supreme Court ruled in February 2026 that the statutory authority used to impose certain tariffs was invalid, but the administration announced plans to impose new tariffs under different authority, leaving the situation unresolved.
Why do government funding cuts matter to Danaher?
A large share of Danaher's Life Sciences customers are universities, government labs, and emerging biotech companies that depend on research grants to pay for equipment and consumables. When governments cut research funding or cancel grants, those customers stop placing orders. In 2025, lower funding levels at academic and government customers was specifically cited as a driver of the Life Sciences segment's core sales decline.
The Life Sciences segment's 7.1% operating margin in 2025 is the number that demands attention. Part of the damage came from one-time impairment charges on trade names and facilities. But the underlying weakness in demand from academic researchers and emerging biotech companies is not a one-time event. The US government in 2025 and into 2026 reduced funding for certain agencies and cancelled or delayed research grants, and Danaher's own management said it expects Life Sciences growth rates to remain below historical levels in 2026 given the current environment.
7.1%
Life Sciences operating margin in 2025, down from 16.9% in 2023, reflecting impairment charges and weak demand from academic and government research customers.
Cepheid's test cartridge pricing has also drawn public attention. In 2023, pressure from public figures led Danaher to cut the price of one tuberculosis test by 20%, while prices for other tests stayed the same. More broadly, Danaher's diagnostics products touch patients and governments in low-income countries, and the political pressure to lower prices on tests for diseases like HIV and tuberculosis is unlikely to go away. That pressure sits alongside the formal regulatory risk: any manufacturing defect or safety problem in a medical device can trigger a recall, lawsuits, and regulatory action that forces products off the market.
Danaher's data privacy exposure is also specific: violations of rules like the European GDPR can carry fines of up to 4% of global revenue. At 2025 revenue levels, that could represent close to $1 billion in a worst-case scenario.
The Bet
Danaher's Biotechnology segment, led by Cytiva and Pall, recovers fully and grows at a pace that more than offsets a structurally weaker Life Sciences segment. The bioprocessing business serves pharmaceutical and contract manufacturing customers who are ramping up production of monoclonal antibodies, cell therapies, and mRNA medicines. If that wave of biological drug manufacturing keeps building, Cytiva and Pall sell more filters, media, and single-use hardware every year without needing new customers. But if drug manufacturers slow their capital spending, cut orders, or find ways to use fewer consumables per batch, the Biotechnology segment's recovery stalls, and there is no obvious internal engine to replace it, given that Life Sciences is already under pressure and Diagnostics is growing only modestly.
Open question
The Biotechnology segment returned to 8.0% sales growth in 2025, and consumables demand from large pharmaceutical companies was the primary driver. The Life Sciences segment, meanwhile, faces a government funding environment that management expects to remain difficult through at least 2026. Is the Biotechnology recovery durable enough to carry the whole company forward, or is Danaher entering a period where two of its three segments are growing slowly while it waits for academic funding and biotech startup spending to come back?
Compiled · 10-K · FY2025
Healthcare Reimbursement and Pricing Controls
Governments and insurance companies worldwide are cutting how much they pay for medical products and services. This includes new U.S. rules like the Inflation Reduction Act that let the government negotiate drug prices, and China's programs that force lower prices. These changes directly reduce the prices the company can charge customers and shrink profits.
Masimo Acquisition Regulatory Risk
The company is trying to buy Masimo Corporation, but antitrust regulators in the U.S. and other countries are scrutinizing the deal. Approval could take longer than expected, be denied entirely, or come with conditions that eliminate the benefits the company expected from the acquisition.
International Business Exposure
About 59% of the company's sales come from outside the U.S., with 11% from China specifically. Political instability, currency changes, trade wars, tariffs, and changing laws in these countries can disrupt operations, increase costs, and reduce demand for products.
Data Privacy and Cybersecurity Compliance
The company must follow strict data protection laws like HIPAA and the European GDPR across many countries. Violations can result in fines up to 4% of global revenue, plus criminal penalties and damage to reputation. Data breaches of patient or customer information are increasingly likely as hackers become more sophisticated.
Product Quality and Safety Liability
Manufacturing defects, design flaws, or safety problems in medical devices can trigger recalls, lawsuits, and regulatory action. These issues can force products off the market, damage customer trust, and result in major financial losses and harm to the company's reputation.
10-K Item 1A · Risk Factors
